Sign in
4

Changes in Ownership

MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000950170-24-043503

Pres., R&D, and CMO sold 2,676 shares at an average $245.99 ($658,258)

  • Pres., R&D, and CMO acquired 2,676 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Option exercise 10b5-1 +2,676 $9.45 $25,288 461,675 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −224 $243.25 $54,487 461,451 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −945 $244.79 $231,325 460,506 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −300 $245.69 $73,706 460,206 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −600 $246.98 $148,186 459,606 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −407 $247.76 $100,838 459,199 D
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Sale 10b5-1 −200 $248.58 $49,716 458,999 D
Derivatives
Taub Rebecca Pres., R&D, and CMO 2024-04-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −2,676 76,564 D
Open-market sales · 2,676 sh · avg $245.99 · $658,258
Loading xslF345X05/ownership.xml…